Our latest videos
Non Regulatory August 10, 2022Invitation to Nanoform’s Interim Report January-June 2022
Non Regulatory July 14, 2022Nanoform and Pharmanovia to breathe new life into iconic medicines
Regulatory June 13, 2022Nanoform Chief of Business Operations Gonçalo Andrade steps down
Nanoform published its Interim Report January-June 2022 on August 25th, 2022, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO Christian Jones. The presentation will be delivered in English.
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
Working together for enhanced drug development
Our nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. We support all phases of drug development, accelerating your time to clinic for GMP manufacture while also increasing possibilities and probabilities of success in taking your product to market.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas